Rapid review on the use of oral fatty acid supplements in the prevention or as adjunct treatment of COVID-19
There is lack of clinical evidence supporting the role of oral fatty acid supplements as prevention and adjunctive
therapy for COVID-19.
- Long-chain polyunsaturated fatty acids (PUFAs) mediate inflammation and adaptive immune responses. Omega-3
fatty acids promote anti‐inflammatory effects and reduce influenza virus replication.
- No clinical evidence supporting the use of oral fatty acid supplements as prevention and adjunctive therapy of
COVID-19 was found.
- We found indirect evidence from one systematic review on acute respiratory distress syndrome (ARDS) and two
longitudinal cohort studies on community-acquired pneumonia that showed non-significant and inconsistent
- The most common known side effects of omega-3-fatty acids are gastrointestinal in nature. They may also cause
allergy and affect blood clotting if taken with other medications that affect clotting.
- There are 2 ongoing clinical trials on eicosapentaenoic fatty acids as an adjunctive therapy to standard oral
nutrition supplements or standard of care in COVID-19 patients.
- WHO Interim guidelines, CDC interim guidelines, Infectious Diseases Society of America COVID-19 treatment
guidelines, and the American Thoracic Society did not give any recommendation on the use of nutritional
supplements in patients with COVID-19.